Q1 EPS Forecast for Axsome Therapeutics Reduced by Analyst

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Investment analysts at Zacks Research lowered their Q1 2027 EPS estimates for Axsome Therapeutics in a note issued to investors on Monday, April 7th. Zacks Research analyst R. Department now expects that the company will earn $0.75 per share for the quarter, down from their prior forecast of $0.92. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. Zacks Research also issued estimates for Axsome Therapeutics’ FY2027 earnings at $5.37 EPS.

A number of other analysts also recently issued reports on AXSM. Leerink Partners raised their target price on Axsome Therapeutics from $110.00 to $150.00 and gave the stock an “outperform” rating in a research note on Monday, February 10th. Morgan Stanley raised their price objective on shares of Axsome Therapeutics from $125.00 to $190.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. Bank of America boosted their target price on shares of Axsome Therapeutics from $143.00 to $167.00 and gave the company a “buy” rating in a report on Tuesday, February 11th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Axsome Therapeutics in a research report on Tuesday, February 11th. They set a “buy” rating and a $176.00 price target on the stock. Finally, Wells Fargo & Company increased their price objective on Axsome Therapeutics from $140.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $169.80.

Axsome Therapeutics Price Performance

NASDAQ:AXSM opened at $97.55 on Tuesday. The stock has a 50 day moving average price of $120.29 and a 200 day moving average price of $101.83. The stock has a market cap of $4.76 billion, a PE ratio of -16.29 and a beta of 0.88. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11. Axsome Therapeutics has a one year low of $64.11 and a one year high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.01. The company had revenue of $118.77 million during the quarter, compared to the consensus estimate of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%.

Institutional Trading of Axsome Therapeutics

Hedge funds have recently modified their holdings of the stock. Boxer Capital Management LLC purchased a new stake in shares of Axsome Therapeutics in the 4th quarter valued at approximately $39,767,000. Lazard Asset Management LLC increased its holdings in Axsome Therapeutics by 525.7% in the fourth quarter. Lazard Asset Management LLC now owns 537,669 shares of the company’s stock valued at $45,492,000 after buying an additional 451,737 shares during the last quarter. Norges Bank acquired a new stake in Axsome Therapeutics in the fourth quarter valued at $34,100,000. BVF Inc. IL lifted its holdings in Axsome Therapeutics by 32.7% during the 4th quarter. BVF Inc. IL now owns 1,388,064 shares of the company’s stock worth $117,444,000 after buying an additional 342,064 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its position in shares of Axsome Therapeutics by 6,002.7% during the 4th quarter. Principal Financial Group Inc. now owns 207,065 shares of the company’s stock worth $17,520,000 after acquiring an additional 203,672 shares in the last quarter. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Axsome Therapeutics

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the transaction, the chief financial officer now owns 42,187 shares of the company’s stock, valued at $5,529,450.09. This trade represents a 6.64 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 22.40% of the stock is currently owned by corporate insiders.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.